Corey M McCann M.D., Ph.D. is a company builder, board member, and investor. He has expertise across healthcare company creation including fundraising, deal-making, clinical & regulatory, and product commercialization with a goal of redefining medicine at scale. Previously, Corey was the President and CEO of Pear Therapeutics, a company developing software-based medicines. Pear's pipeline of products and product candidates spanned therapeutic areas, including the first three apps with disease treatment claims from FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first app to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first app to receive Breakthrough Designation. Prior, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at multiple healthcare companies. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.